The two current anti-hypnozoite 8-aminoquinolines, primaquine (31) and tafenoquine (32, 33), require glucose-6-phosphate dehydrogenase deficiency testing, which is an impediment (time, extra clinical visit, cost, and accuracy of point of care test) to widespread drug implementation (34, –, 37). Here, G6PD is linked to hyperinsulinemic hypoglycemia, familial, 4.